
Starting #ISLB2026 in Madrid! @TarazonaNoelia and @jberchuck starting with clinical applications in CRC and Prostate Cancer Chairs @javierDcastro & @AyaHelali @isliquidbiopsy
✓Medical Oncologist, PhD, Clinician Scientist, Precision Oncology, Novice Crossfitter

Starting #ISLB2026 in Madrid! @TarazonaNoelia and @jberchuck starting with clinical applications in CRC and Prostate Cancer Chairs @javierDcastro & @AyaHelali @isliquidbiopsy

Inspiring discussions at #ISLB2026 first session on Clinical Applications of Liquid Biopsy @isliquidbiopsy @UmbertoMalapel1 @JavierCortesMD @jberchuck @AyaHelali @TarazonaNoelia #MaryRedman #AtochaRomero

Precision oncology🎯 is evolving—but how do we distinguish a promising molecular target🧬 from one supported by evidence strong enough to guide treatment? sciencedirect.com/science/ar… The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology ESCAT v2 updates the ESMO framework for assessing molecular target actionability in precision oncology. ➡️ The revised classification refines evidence certainty within actionable tiers, introduces formal tumour-agnostic eligibility criteria through ETAC-S, and distinguishes non-predictive biomarkers from ineffective biomarker–therapy matches. ➡️ A complementary four-level resistance scale classifies evidence from clinically validated resistance to preclinical findings. ✅️ Together, these updates support more consistent interpretation of sensitivity and resistance biomarkers, helping guide therapeutic decisions and research priorities. @AyaHelali, @niamhjcoleman, @ekocakavuk, @clare__turnbull, @FerMosele, @CDebyaniPhD, @rdienstmann, @herbloong, @DMBranco, @quimmateo, @BenWestphalen

🆕 Article in press - The ESMO Scale for Clinical Actionability of molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology. 🔗tinyurl.com/4bdwu56h @AyaHelali

#PrecisionOncology is generating more biomarker data than ever, adding complexity to treatment decisions. ESCAT v2 helps oncologists evaluate genomic alterations, interpret actionable biomarkers and classify resistance biomarkers. 🔗 ow.ly/mimb50ZZME9 @FAndreMD @AyaHelali @BenWestphalen @quimmateo

Looking forward to speaking this Sunday at #WCLC26 @IASLC! Excited to share our work on #TumorDormancy #brain #Metastasis alongside @AyaHelali, Julie George, John Heymach, @ManelEsteller. See you at 5:30 PM! @oncoalert @oncodaily @IcahnMountSinai cattendee.abstractsonline.co…

✈️ Heading to #Seoul, #Korea to deliver lecture at the World Conference on #Lung #Cancer #WCLC26 @IASLC ! Can't wait to learn, spark new collaborations, and connect with brilliant co-speakers @BravoCorderoLab @AyaHelali Julie George @DTG_Cologne and John Heymach @UTMDAnderson ! 🔬🫁 cattendee.abstractsonline.co…

Tumour-agnostic therapies are accelerating, but implementation is lagging behind science. Looking forward to discussing where the real gaps are at this upcoming @myESMO Therapeutic Landscapes webinar. @AyaHelali @BenWestphalen @dcorreiamartins @StefanMichiels @OncoAlert

Thx @ErulEnes for spotlighting #ISLB2025's stakeholder discussions! Key takeaways: the integration of AI may revolutionise liquid biopsy, integrating multi-omics for real-time tumor tracking and treatment modification. #PrecisionMedicine #MRD #liquidbiopsy @hkumed




🚨Our @CellReports study reveals how #ecDNA acts as a "rogue amplifier" in #GBM tumors Massive thanks to collaborators #HongKongGenomeInstitute and the team @hkumed. Most importantly, we're grateful to patients who made this possible. sciencedirect.com/science/ar…

What an absolute pleasure to share that stage with you all at #WCLC25 @IASLC @CespedesMontse @HaradaGuilherme @MaraverLab @triparnasen 💫

Prof @AyaHelali -precautions/pitfalls in reporting exploratory biomarker analyses (No single guideline addresses this); Prof @herbloong increasing importance of PROs in early phase clin trials incl dose esc decisions-it’s complicated! #ESMOTATAsia25 @myESMO

Also had the opportunity to highlight our @CUHKMedicine @hkumed study that was published in @myESMO @ESMO_Open some years ago look at #comorbidities of patients w/ #sarcomas. We have identified that 10% of #newly diagnosed #sarcoma patients in #hongkong had #DiabetesMellitus, 5% w/ history of #CVA and 4% w/ #IHD. More co-morbidities associated with poorer prognosis and survival, independent of age. There maybe a role for #GPs and #primarycare colleagues to be more involved in #earlydetection and #identification of #atrisk individuals. @CarlosWongHKU